The law firm said the case covers Erasca share purchases from January 14, 2025 to April 26, 2026 and alleges misleading statements tied to preclinical data for ERAS-0015.
Schall, Brown & Schwartz LLP said investors who bought Erasca, Inc. shares during the January 14, 2025 to April 26, 2026 class period have until August 10, 2026 to seek appointment as lead plaintiff in a securities class action. The lawsuit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, a U.S. Securities and Exchange Commission (market regulator) anti-fraud rule. According to the complaint described in the release, Erasca's preclinical data on ERAS-0015 relied on an improper comparison to Revolution Medicines, Inc., creating risk of violating patent protections and leaving the company without a basis for optimistic statements about the drug candidate. The release says those alleged misstatements were materially misleading throughout the class period and that investors suffered damages when the market learned the truth. SBS added that investors do not need to serve as lead plaintiff to share in any recovery, and noted that the class has not yet been certified, meaning investors who take no action can remain absent class members.